Key points from article :
LyGenesis is conducting a groundbreaking clinical trial to grow a "mini liver" within patients suffering from end-stage liver disease.
Donated liver cells (hepatocytes) are injected into a patient's lymph node.
These cells are expected to multiply, transforming the lymph node into a functional liver-like organ.
The trial is led by LyGenesis, a Pittsburgh-based biotechnology company.
The first procedure was performed in Houston on March 25th, 2024.
The initial patient is reported to be recovering well, but it could take months for the new liver-like organ to fully form.
This therapy has the potential to revolutionise treatment for end-stage liver disease, addressing the critical shortage of donor organs and offering hope to patients who wouldn't qualify for traditional transplants.
